期刊
CLINICAL & TRANSLATIONAL ONCOLOGY
卷 17, 期 4, 页码 264-273出版社
SPRINGER INTERNATIONAL PUBLISHING AG
DOI: 10.1007/s12094-014-1252-0
关键词
Biomarkers; CRC; EGFR; KRAS; NRAS
类别
资金
- Merck
- Sanofi
- Roche
Publication of this consensus statement is a joint initiative of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM), intended to revise and update the diagnostic and treatment recommendations published 2 years ago on biomarker use and the management of patients with colorectal carcinoma (CRC), thereby providing an opportunity to improve healthcare efficiency and resource use in these patients. This expert group recommends testing for KRAS and NRAS status in all patients with metastatic CRC being considered for anti-epidermal growth factor receptor (anti-EGFR) therapy, as this type of treatment should only be used in patients not harbouring mutations in these genes. In contrast, testing for BRAF, EGFR, PI3K and PTEN mutation status is not necessary for therapeutic decision making, so does not need to be done routinely.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据